帕博利珠单抗对比安慰剂用于已切除IIB或IIC期黑色素瘤辅助治疗(KEYNOTE-716):多中心、双盲、随机、3期试验的无远处转移生存结果
KEYNOTE-716研究纳入976例已完全切除的IIB或IIC期皮肤黑色素瘤患者,随机接受帕博利珠单抗或安慰剂辅助治疗。中位随访27.4个月时,帕博利珠单抗显著改善无远处转移生存(HR 0.64,95%CI 0.47-0.88,p=0.0029),并持续降低复发风险(HR 0.64,95%CI 0.50-0.84)。
要点
- 帕博利珠单抗组无远处转移生存显著优于安慰剂组(HR 0.64,95%CI 0.47-0.88,p=0.0029)。
- 帕博利珠单抗组复发风险持续低于安慰剂组(HR 0.64,95%CI 0.50-0.84)。
- 治疗相关严重不良事件:帕博利珠单抗组49例(10%)vs 安慰剂组11例(2%),未报告治疗相关死亡。
核心结论
- 辅助帕博利珠单抗是已切除IIB和IIC期黑色素瘤的有效治疗选择,较安慰剂显著改善无远处转移生存并持续降低复发风险,不良事件特征与既往帕博利珠单抗研究一致。
- 帕博利珠单抗在辅助治疗中的总体获益-风险比继续为正。
研究设计与样本
- KEYNOTE-716是一项在16个国家160个学术医学中心和医院开展的多中心、双盲、安慰剂对照、交叉或再挑战、随机、3期试验。
- 纳入年龄≥12岁、新诊断、完全切除、组织学确诊的IIB期(T3b或T4a)或IIC期(T4b)皮肤黑色素瘤、前哨淋巴结活检阴性、ECOG体能状态0-1的患者。
- 2018年9月23日至2020年11月4日期间,976例患者按1:1随机分配至帕博利珠单抗组(n=487)或安慰剂组(n=489)。
- 帕博利珠单抗200 mg(儿童患者2 mg/kg,最大200 mg)或安慰剂静脉给药,每3周一次,共17个周期(第1部分),直至疾病复发或不可接受毒性。
- 主要终点为研究者评估的无复发生存,本次报告预设第三次 interim 分析的无远处转移生存(次要终点)。
主要发现
- 中位随访27.4个月(IQR 23.1-31.7)时,两组中位无远处转移生存均未达到(95%CI NR-NR)。
- 帕博利珠单抗组无远处转移生存显著优于安慰剂组(HR 0.64,95%CI 0.47-0.88,p=0.0029)。
- 帕博利珠单抗组中位无复发生存为37.2个月(95%CI NR-NR),安慰剂组未达到(95%CI NR-NR)。
- 帕博利珠单抗组复发风险持续低于安慰剂组(HR 0.64,95%CI 0.50-0.84)。
- 最常见3级或更严重不良事件:高血压(帕博利珠单抗组16/483例[3%] vs 安慰剂组17/486例[4%])、腹泻(8例[2%] vs 1例[<1%])、皮疹(7例[1%] vs 2例[<1%])、自身免疫性肝炎(7例[1%] vs 2例[<1%])、脂肪酶升高(6例[1%] vs 8例[2%])。
关键数值与推荐
- 帕博利珠单抗组治疗相关严重不良事件49例(10%),安慰剂组11例(2%)。
- 未报告治疗相关死亡。
临床怎么用
- 原文结论认为辅助帕博利珠单抗是已切除IIB和IIC期黑色素瘤的有效治疗选择,总体获益-风险比继续为正。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with stage IIB or IIC melanoma who undergo surgery alone are at a substantial risk for disease recurrence. Adjuvant pembrolizumab significantly improved recurrence-free survival versus placebo in stage IIB or IIC melanoma in the first interim analysis of the KEYNOTE-716 trial. Here, we report results from the secondary endpoint of distant metastasis-free survival (prespecified third interim analysis), and recurrence-free survival with longer follow-up. METHODS: KEYNOTE-716 is a multicentre, double-blind, placebo-controlled, crossover or rechallenge, randomised, phase 3 trial done at 160 academic medical centres and hospitals across 16 countries. Eligible patients were aged 12 years and older with newly-diagnosed, completely resected, and histologically confirmed stage IIB (T3b or T4a) or IIC (T4b) cutaneous melanoma; negative sentinel lymph node biopsy; and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) to receive either 200 mg of pembrolizumab (2 mg/kg up to a maximum of 200 mg in paediatric patients) or placebo, both intravenously, every 3 weeks for 17 cycles (part 1) or until disease recurrence or unacceptable toxicity. Eligible patients with disease recurrence could receive further treatment with pembrolizumab in the part 2 crossover or rechallenge phase. Randomisation was done using an interactive response technology system and stratified by T category and paediatric status. The primary endpoint was investigator-assessed recurrence-free survival (assessed here with longer follow-up), and we report the prespecified third interim analysis of distant metastasis-free survival (secondary endpoint). Efficacy analyses were done in the intention-to-treat population (all patients who were randomly assigned, according to assigned group) and safety was assessed in all patients who were randomly assigned and received at least one dose of trial treatment, according to the treatment received. KEYNOTE-716 is registered at ClinicalTrials.gov, NCT03553836, and has completed recruitment. FINDINGS: Between Sept 23, 2018, and Nov 4, 2020, 976 patients were randomly assigned to receive pembrolizumab (n=487) or placebo (n=489). At a median follow-up of 27·4 months (IQR 23·1-31·7), median distant metastasis-free survival was not reached (95% CI not reached [NR]-NR) in either group. Pembrolizumab significantly improved distant metastasis-free survival (hazard ratio [HR] 0·64, 95% CI 0·47-0·88, p=0·0029) versus placebo. Median recurrence-free survival was 37·2 months (95% CI NR-NR) in the pembrolizumab group and not reached in the placebo group (95% CI NR-NR). The risk of recurrence remained lower with pembrolizumab versus placebo (HR 0·64, 95% CI 0·50-0·84). The most common grade 3 or worse adverse events were hypertension (16 [3%] of 483 patients in the pembrolizumab group vs 17 [4%] of 486 patients in the placebo group), diarrhoea (eight [2%] vs one [<1%]), rash (seven [1%] vs two [<1%]), autoimmune hepatitis (seven [1%] vs two [<1%]), and increased lipase (six [1%] vs eight [2%]). Treatment-related serious adverse events occurred in 49 (10%) patients in the pembrolizumab group and 11 (2%) patients in the placebo group. No treatment-related deaths were reported. INTERPRETATION: Adjuvant pembrolizumab is an efficacious treatment option for resected stage IIB and IIC melanoma, with significant improvement in distant-metastasis free survival versus placebo and continued reduction in the risk of recurrence with an adverse event profile consistent with previous studies of pembrolizumab. The overall benefit-risk of pembrolizumab continues to be positive in the adjuvant setting. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co.
引用
- Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022. PMID: 36265502. doi:10.1016/S1470-2045(22)00559-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。